{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:25:44Z","timestamp":1772166344839,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Epithelial ovarian cancer (EOC) has the worst prognosis in all of gynecologic malignant tumors because of its high recurrence and eventually chemo-resistance. Early diagnosis of recurrence is crucial to avoid diffuse dissemination. Failure of traditional treatment in recurrent epithelial ovarian cancer remains a challenge for clinicians. On the other hand,\n                      <jats:sup>125<\/jats:sup>\n                      I brachytherapy has been accepted as a useful and hopeful treatment for multiple advanced cancers in recent years. However, its success in advanced epithelial ovarian cancer is limited. Here we report a case of recurrent ovarian cancer who had been early diagnosis of isolated recurrence and successfully treated with\n                      <jats:sup>125<\/jats:sup>\n                      I seeds implantation during suboptimal cytoreductive surgery.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      A 59-year-old woman presented with recurrent epithelial ovarian cancer who have had a history of ovarian cancer stage IIIB and an R0 resection had been achieved nearly 2\u2009years before presented in our hospital. She underwent suboptimal secondary cytoreductive surgery after four cycles of chemotherapy with little effectiveness and severe chemotherapy-related side effects. Approximately 70% of the cancer-bulk was resected during surgery. For residual lesion which fixed around the right ureter and right external iliac vessel,\n                      <jats:sup>125<\/jats:sup>\n                      I seeds implantation was performed. Postoperatively, the patient was treated with two cycles of combination chemotherapy with paclitaxel and carboplatin. The patient was free of disease at 26\u2009months\u2019 follow-up period.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In recurrent EOC patients with unresectable isolated lesion, salvage 125I seeds implantation are feasible and may contribute to survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13048-020-00744-2","type":"journal-article","created":{"date-parts":[[2020,11,29]],"date-time":"2020-11-29T22:02:13Z","timestamp":1606687333000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Improved prognosis for recurrent epithelial ovarian cancer by early diagnosis and 125I seeds implantation during suboptimal secondary cytoreductive surgery: a case report and literature review"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2240-8659","authenticated-orcid":false,"given":"Lin","family":"Xiao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junying","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuexun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,30]]},"reference":[{"issue":"3","key":"744_CR1","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1097\/AOG.0b013e318264f794","volume":"120","author":"LA Baldwin","year":"2012","unstructured":"Baldwin LA, Huang B, Miller RW, Tucker T, Goodrich ST, Podzielinski I, DeSimone CP, Ueland FR, van Nagell JR, Seamon LG. Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol. 2012;120(3):612\u20138.","journal-title":"Obstet Gynecol"},{"issue":"1","key":"744_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.tjog.2019.10.003","volume":"59","author":"WC Chen","year":"2020","unstructured":"Chen WC, Huang HJ, Chang TC, Chou HH. Dose-dense chemotherapy with weekly paclitaxel and 3-weekly carboplatin for recurrent ovarian cancer. Taiwan J Obstet Gynecol. 2020;59(1):21\u20137.","journal-title":"Taiwan J Obstet Gynecol"},{"issue":"22","key":"744_CR3","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016;375(22):2154\u201364.","journal-title":"N Engl J Med"},{"issue":"10106","key":"744_CR4","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949\u201361.","journal-title":"Lancet"},{"issue":"9","key":"744_CR5","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274\u201384.","journal-title":"Lancet Oncol"},{"issue":"4","key":"744_CR6","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1093\/annonc\/mdz018","volume":"30","author":"JF Liu","year":"2019","unstructured":"Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel BJ, Buss MK, Nattam SR, Hurteau J, et al. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol. 2019;30(4):551\u20137.","journal-title":"Ann Oncol"},{"issue":"1","key":"744_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-020-00629-4","volume":"13","author":"J Ni","year":"2020","unstructured":"Ni J, Zhou R, Cheng X, Xu X, Guo W, Chen X. Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series. J Ovarian Res. 2020;13(1):29.","journal-title":"J Ovarian Res"},{"issue":"9","key":"744_CR8","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1073\/pnas.0611533104","volume":"104","author":"J Hamanishi","year":"2007","unstructured":"Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A. 2007;104(9):3360\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"744_CR9","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ygyno.2016.03.008","volume":"141","author":"JR Webb","year":"2016","unstructured":"Webb JR, Milne K, Kroeger DR, Nelson BH. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. Gynecol Oncol. 2016;141(2):293\u2013302.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"744_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ygyno.2018.08.012","volume":"151","author":"JS Chang","year":"2018","unstructured":"Chang JS, Kim SW, Kim YJ, Kim JY, Park SY, Kim JH, Jang TK, Kim YB. Involved-field radiation therapy for recurrent ovarian cancer: Results of a multi-institutional prospective phase II trial. Gynecol Oncol. 2018;151(1):39\u201345.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"744_CR11","doi-asserted-by":"publisher","first-page":"e311","DOI":"10.1634\/theoncologist.2019-0309","volume":"25","author":"G Macchia","year":"2020","unstructured":"Macchia G, Lazzari R, Colombo N, Laliscia C, Capelli G, D'Agostino GR, Deodato F, Maranzano E, Ippolito E, Ronchi S, et al. A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups. Oncologist. 2020;25(2):e311\u201320.","journal-title":"Oncologist"},{"issue":"3","key":"744_CR12","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.ygyno.2019.09.020","volume":"155","author":"C Marchetti","year":"2019","unstructured":"Marchetti C, Rosati A, Scaletta G, Pietragalla A, Arcieri M, Ergasti R, Palluzzi E, Scambia G, Fagotti A. Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study. Gynecol Oncol. 2019;155(3):400\u20135.","journal-title":"Gynecol Oncol"},{"issue":"20","key":"744_CR13","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","volume":"381","author":"RL Coleman","year":"2019","unstructured":"Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, Kim JW, Park SY, Kim BG, Nam JH, et al. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. N Engl J Med. 2019;381(20):1929\u201339.","journal-title":"N Engl J Med"},{"issue":"3","key":"744_CR14","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s00261-018-1677-y","volume":"44","author":"L Manganaro","year":"2019","unstructured":"Manganaro L, Gigli S, Antonelli A, Saldari M, Tomao F, Marchetti C, Anastasi E, Laghi A. Imaging strategy in recurrent ovarian cancer: a practical review. Abdom Radiol (NY). 2019;44(3):1091\u2013102.","journal-title":"Abdom Radiol (NY)"},{"issue":"2","key":"744_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/1097-0142(194807)1:2<177::AID-CNCR2820010203>3.0.CO;2-A","volume":"1","author":"A Brunschwig","year":"1948","unstructured":"Brunschwig A. Complete excision of pelvic viscera for advanced carcinoma; a one-stage abdominoperineal operation with end colostomy and bilateral ureteral implantation into the colon above the colostomy. Cancer. 1948;1(2):177\u201383.","journal-title":"Cancer"},{"issue":"10","key":"744_CR16","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1002\/1097-0142(19910515)67:10<2467::AID-CNCR2820671013>3.0.CO;2-K","volume":"67","author":"SK Sharma","year":"1991","unstructured":"Sharma SK, Forgione H, Isaacs JH. Iodine-125 interstitial implants as salvage therapy for recurrent gynecologic malignancies. Cancer. 1991;67(10):2467\u201371.","journal-title":"Cancer"},{"issue":"7","key":"744_CR17","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.4103\/jcrt.JCRT_938_17","volume":"14","author":"J Lu","year":"2018","unstructured":"Lu J, Huang W, Wang Z, Gong J, Ding X, Chen Z, Xia N, Yang N, Wu Z, Wang C, et al. The safety and efficacy of interstitial (125)I seed implantation brachytherapy for metastatic epidural spinal cord compression. J Cancer Res Ther. 2018;14(7):1549\u201355.","journal-title":"J Cancer Res Ther"},{"issue":"2","key":"744_CR18","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.brachy.2017.11.015","volume":"17","author":"W Zhang","year":"2018","unstructured":"Zhang W, Li J, Li R, Zhang Y, Han M, Ma W. Efficacy and safety of iodine-125 radioactive seeds brachytherapy for advanced non-small cell lung cancer-A meta-analysis. Brachytherapy. 2018;17(2):439\u201348.","journal-title":"Brachytherapy"},{"issue":"4","key":"744_CR19","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/S0360-3016(99)00069-3","volume":"44","author":"S Nag","year":"1999","unstructured":"Nag S, Beyer D, Friedland J, Grimm P, Nath R. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 1999;44(4):789\u201399.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"744_CR20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.4103\/jcrt.JCRT_888_17","volume":"14","author":"J Wang","year":"2018","unstructured":"Wang J, Chai S, Zheng G, Jiang Y, Ji Z, Guo F, Zhuang H, Zhang K. Expert consensus statement on computed tomography-guided (125)I radioactive seeds permanent interstitial brachytherapy. J Cancer Res Ther. 2018;14(1):12\u20137.","journal-title":"J Cancer Res Ther"},{"issue":"3","key":"744_CR21","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/S0360-3016(01)02728-6","volume":"52","author":"BJ Monk","year":"2002","unstructured":"Monk BJ, Tewari KS, Puthawala AA, Syed AM, Haugen JA, Burger RA. Treatment of recurrent gynecologic malignancies with iodine-125 permanent interstitial irradiation. Int J Radiat Oncol Biol Phys. 2002;52(3):806\u201315.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"744_CR22","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1148\/rg.2015140293","volume":"35","author":"SH Goudreau","year":"2015","unstructured":"Goudreau SH, Joseph JP, Seiler SJ. Preoperative Radioactive Seed Localization for Nonpalpable Breast Lesions: Technique, Pitfalls, and Solutions. Radiographics. 2015;35(5):1319\u201334.","journal-title":"Radiographics"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-020-00744-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13048-020-00744-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-020-00744-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,29]],"date-time":"2020-11-29T22:03:04Z","timestamp":1606687384000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-020-00744-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,30]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["744"],"URL":"https:\/\/doi.org\/10.1186\/s13048-020-00744-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-38148\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-38148\/v2","asserted-by":"object"}]},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,30]]},"assertion":[{"value":"25 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This paper was approved by the Ethics Committee of the institutional review board (IRB) of Chongqing Medical University. and a signed informed consent has been obtained from the patient.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for the publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"141"}}